Adjuvant chemotherapy for non-small cell lung cancer.

  title={Adjuvant chemotherapy for non-small cell lung cancer.},
  author={Edward J. Crane and George Rajan Simon},
  journal={Current treatment options in oncology},
  volume={7 1},
Studies of adjuvant chemotherapy for non-small cell lung cancer (NSCLC) did not provide a consistent disease-free survival or overall survival benefit in the 1980s and early 1990s. However, recently reported studies have changed the practice of NSCLC treatment, for which adjuvant chemotherapy is now considered the standard of care. This review outlines the issues that may have limited the detection of beneficial effects of adjuvant chemotherapy in early trials and provides detailed analysis of… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 17 extracted citations

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2016

Similar Papers

Loading similar papers…